KAMS

Kongsberg Aviation Maintenance Services AS selects IFS Cloud to streamline operations and strengthen asset reliability

Retrieved on: 
星期一, 一月 8, 2024
Cloud, MRO, TAT, Acquisition, Air force, KAMS, CGI, CRM, Growth, Automation, Environment, Maintenance (technical)

LONDON, Jan. 8, 2024 /PRNewswire/ -- IFS, the global cloud enterprise software company, today announced that Kongsberg Aviation Maintenance Services AS (KAMS), a leading supplier of maintenance, repair and overhaul (MRO) services within the aviation industry for both military and civil organizations has selected IFS Cloud to streamline operational efficiency and build long-term asset resilience.

Key Points: 
  • IFS Cloud's ERP, MRO solution to enable Kongsberg company to increase automation driving efficiency and build long-term asset resilience and reliability.
  • LONDON, Jan. 8, 2024 /PRNewswire/ -- IFS , the global cloud enterprise software company, today announced that Kongsberg Aviation Maintenance Services AS (KAMS), a leading supplier of maintenance, repair and overhaul (MRO) services within the aviation industry for both military and civil organizations has selected IFS Cloud to streamline operational efficiency and build long-term asset resilience.
  • The use of IFS Cloud will enable KAMS to improve turnaround time (TAT) and reduce costs, helping to facilitate business expansion and new customer acquisition.
  • The comprehensive functionality of IFS Cloud will also help KAMS optimize processes for enhanced productivity, allowing it to improve resource allocation, sourcing, planning, maintenance execution, and financial reporting.

Relevate Health Acquires ConneXion360

Retrieved on: 
星期一, 四月 25, 2022
CEO, Behavior, Health, OnDemand, Machine learning, Culturally relevant teaching, ROI, Growth, MM, Technology, KAMS, HCPS, Digital, National Broadcasting Commission, Solution, Health care, Library and information science, Acquisition, HCP, Health system, Reps, Sales, Public relations, Financial services

 CINCINNATI, April 25, 2022 /PRNewswire/ -- Relevate Health solidifies its position as the market leader in Healthcare Professional (HCP) omnichannel engagement with the acquisition of Dallas-based ConneXion360.   With this acquisition, Relevate Health now provides its omnichannel solutions and agency services to more than 185 brands from 90 pharmaceutical, biotech, and medical device manufacturers, as well as 24 hospital systems. 

Key Points: 
  • CINCINNATI, April 25, 2022 /PRNewswire/ -- Relevate Health solidifies its position as the market leader in Healthcare Professional (HCP) omnichannel engagement with the acquisition of Dallas-based ConneXion360.
  • "Bringing ConneXion360's 1:1 engagement, Key Account Messaging, immersive video, and national broadcast capabilities into the Relevate Health suite of products and technology offer new brand-building opportunities for our clients," said Relevate Health CEO Jeff Spanbauer.
  • "Relevate Health is known for its use of data and machine learning to create locally relevant messages that are scalable," said George Griffith, Co-Founder & CEO of ConneXion360.
  • The acquisition of ConneXion360 marks the third transaction by Relevate Health since taking on funding from Denver-based private equity firm Mountaingate Capital in late 2020.

Ocular Therapeutix™ Reports Fourth Quarter and Year-End 2021 Financial Results and Business Update

Retrieved on: 
星期一, 二月 28, 2022
Health, Research, Pharmaceutical, Science, Optical, Biotechnology, Eye, Sealant, Depreciation, Travoprost, Omicron, ITT, Dexamethasone, Compliance, Investor, Population, Allergic conjunctivitis, Webcast, International, IOP, Glaucoma, Pain, Inflammation, Intraocular pressure, Security (finance), NASDAQ, Slit lamp, ID, Research, Retina, COVID-19, Duane syndrome, Company, Angiogenesis, Quarter, Clinical trial, Safety, G&A, U.S. Securities and Exchange Commission, Review, AMD, Axitinib, KAMS, Private Securities Litigation Reform Act, FDA, Patient, Marketing, Ocular hypertension, Royal, Software, Pharmaceutical industry, Medical imaging, Telescopic sight, Medical device, Ocular Therapeutix, Inc., DEXTENZA, OCULAR THERAPEUTIX, INC., DEXTENZA

In the fourth quarter of 2021, in-market purchases were in excess of 29,000 billable units, representing sequential quarterly growth of approximately 17%.

Key Points: 
  • In the fourth quarter of 2021, in-market purchases were in excess of 29,000 billable units, representing sequential quarterly growth of approximately 17%.
  • In October 2021, the Company received supplemental FDA approval expanding DEXTENZAs label to include the treatment of ocular itching associated with allergic conjunctivitis.
  • General and administrative expenses were $7.5 million for the fourth quarter versus $6.6 million in the comparable quarter of 2020.
  • Members of the Ocular Therapeutix management team will host a live conference call and webcast today at 4:30 pm Eastern Time to review the Company's financial results and provide a general business update.

Theratechnologies Strengthens Global Commercial Capabilities by Launching Internal Field Force

Retrieved on: 
星期二, 二月 15, 2022
NASDAQ, Patient, CLS, Library and information science, Judgement, Company, SEDAR, Public expenditure, EDGAR, Forward-looking statement, Ownership, FDA, Sale, Marketing, KAMS, Growth, COVID-19, TSX, GLOBE, Risk management, Pharmaceutical industry

MONTREAL, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the strengthening of its global commercial capabilities by launching an internal sales force. Also, to better serve patients and health care providers, we will further strengthen our medical affairs team to focus on disease education and treatment alternatives. Top performers of the current field force will join the Company from its partner contract sales organization and new, experienced sales representatives will be hired to create a competitive field force, leading to superior performance and faster growth from our commercial portfolio. Key account managers (KAMs), medical sales liaisons (MSLs), and community liaisons (CLs) based in the United States will join Theratechnologies’ new internal sales and medical affairs team.

Key Points: 
  • Top performers of the current field force will join the Company from its partner contract sales organization and new, experienced sales representatives will be hired to create a competitive field force, leading to superior performance and faster growth from our commercial portfolio.
  • Key account managers (KAMs), medical sales liaisons (MSLs), and community liaisons (CLs) based in the United States will join Theratechnologies new internal sales and medical affairs team.
  • Paul Lvesque, President and Chief Executive Officer, Theratechnologies, said, We now possess the necessary critical mass to bring aboard a dedicated field force as we aim towards advancing the growth of our commercial franchises.
  • This and other positive factors have led to the decision to transition from a contract field force model to one staffed by Theratechnologies employees.